Study Title

68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers

Study Details

Description:

To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.

Sponsor:

The First Affiliated Hospital of Xiamen University

Contacts:

Liang Zhao

wzhaoliang01@163.com

86 0592-213-7366

Government Study Link:

NCT06754345 - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga-NK224
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • PD-L1

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468